Literature DB >> 17211331

Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases.

Nathalie Baize1, Béatrice Gerard, Harry Bleiberg, François Caroli-Bosc, Frédéric Berthier, Hughes Legendre, Jean-Claude Pector, Alain Hendlisz.   

Abstract

OBJECTIVES: To evaluate long-term survival of patients resected for primarily unresectable colorectal liver metastases downstaged by systemic chemotherapy.
METHODS: Among a group of 82 patients with advanced colorectal cancer, 39 had unresectable liver metastases. After treatment with systemic 3-weekly 5FU/folinic acid/oxaliplatin chemotherapy, the outcome of 11 patients made resectable thanks to chemotherapy was compared to that of 28 patients who were not. Criteria for non-resectability consisted of diffuse bilobar invasion with inability to achieve complete resection, unilobar or bilobar invasion plus vascular extension (invasion of inferior vena cava or 2 supra-hepatic veins plus continuity with the 3rd) or involvment of hepatic pedicle. Before and after surgery, CT scan evaluation was performed every 2 months. Progression free survival was defined as the time between starting chemotherapy and recurrence of the disease. We used Kaplan-Meier survival curves and log-rank test for comparisons, P values were two-sided and considered significant if<0.05.
RESULTS: Progression free survival times were 14 and 6 months, median overall survival were 60 and 18.5 months, respectively, in favour of secondary resected subjects.
CONCLUSION: Considering the magnitude of the survival benefit, one may question the need and feasibility for trials to assess more formally the impact of surgery in that setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17211331     DOI: 10.1016/s0399-8320(06)73553-9

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  5 in total

Review 1.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

2.  Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.

Authors:  Magali Rouyer; Denis Smith; Christophe Laurent; Yves Becouarn; Rosine Guimbaud; Pierre Michel; Nicole Tubiana-Mathieu; Aurélie Balestra; Jérémy Jové; Philip Robinson; Pernelle Noize; Nicholas Moore; Alain Ravaud; Annie Fourrier-Réglat
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

3.  An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer.

Authors:  Marco Agostini; Klaus-Peter Janssen; Il-Jin Kim; Edoardo D'Angelo; Silvia Pizzini; Andrea Zangrando; Carlo Zanon; Chiara Pastrello; Isacco Maretto; Maura Digito; Chiara Bedin; Igor Jurisica; Flavio Rizzolio; Antonio Giordano; Stefania Bortoluzzi; Donato Nitti; Salvatore Pucciarelli
Journal:  Oncotarget       Date:  2015-10-20

4.  Technical development of a new semispherical radiofrequency bipolar device (RONJA): ex vivo and in vivo studies.

Authors:  Petr Vavra; Marek Penhaker; Jan Grepl; Jana Jurcikova; Jiri Palecek; Michal Crha; Jana Nowakova; Martin Hasal; Martina Skrobankova; Petr Ostruszka; Peter Ihnat; Patricie Delongova; Dana Salounova; Nagy A Habib; Pavel Zonca
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

5.  Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy.

Authors:  Da Xu; Xiao-Feng Liu; Xiao-Luan Yan; Kun Wang; Bao-Cai Xing
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.